Want to see CH:SDZ full AI Analyst Report?

Sandoz Group Ltd (SDZ) Price & Analysis

33 Followers

SDZ Stock Chart & Stats

CHF67.16

-CHF0.79(-1.99%)

At close: Mar 06 4:00 PM EST

CHF67.16

-CHF0.79(-1.99%)

Day’s Range― - ―

52-Week RangeCHF43.66 - CHF74.72

Previous CloseN/A

Volume450.36K

Average Volume (3M)677.45K

Market Cap

CHF30.45B

Enterprise ValueCHF41.20B

Total Cash (Recent Filing)CHF1.74B

Total Debt (Recent Filing)CHF5.68B

Price to Earnings (P/E)39.9

Beta0.81

Next Earnings

Aug 05, 2026

EPS Estimate

1.45

Next Dividend Ex-DateN/A

Dividend Yield1.02%

Share Statistics

EPS (TTM)2.13

Shares Outstanding440,000,000

10 Day Avg. Volume616,025

30 Day Avg. Volume677,447

Financial Highlights & Ratios

PEG Ratio0.00

Price to Book (P/B)3.35

Price to Sales (P/S)2.82

P/FCF Ratio38.83

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

CHF74.67

Price Target Upside11.18% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering6

EPS Forecast (FY)4.08

Revenue Forecast (FY)CHF12.12B

Bulls Say, Bears Say

Bulls Say

Revenue & Profitability ReboundA ~25% revenue increase and net margin recovery to ~8% in 2025 indicate the company regained pricing and volume traction after prior weakness. This kind of operational rebound signals sustainable revenue drivers and improved operating leverage from core generics and biosimilars, supporting multi‑period cash generation and investor visibility.

Consistently Strong Gross MarginsStable gross margins near 46–48% point to durable unit economics from low-cost manufacturing and product mix advantages in off‑patent medicines and biosimilars. Reliable gross margins help buffer price pressure in generics, supporting long‑term profitability even if top‑line growth cycles through tender and reimbursement dynamics.

Material Cash Flow Recovery In 2025A rebound to ~€1.6B operating cash flow and ~€0.81B free cash flow improves the firm's ability to fund operations, invest in capacity, pay down debt or sustain payouts. Strong cash generation after prior weakness demonstrates improved conversion of earnings to cash, enhancing medium‑term financial flexibility and resilience.

Bears Say

Earnings And FCF VolatilityLarge year‑to‑year swings in free cash flow and earnings highlight sensitivity to working capital, tender timing and investment cycles common in generics. This volatility makes forecasting cash available for reinvestment or debt reduction harder, increasing operating and financing risk over the next several quarters.

Rising Absolute Debt LevelsAlthough leverage is moderate, rising absolute debt from 2023–2025 raises interest and refinancing exposure. Higher debt can constrain capital allocation for R&D, capacity or M&A, and reduces flexibility to absorb future margin or revenue shocks, heightening balance‑sheet risk if cash generation weakens.

Historic Data Outlier Reduces Trend ConfidenceAn extreme 2022 outlier in debt and ROE undermines multi‑year comparability and trend analysis. This weakens confidence in projecting near‑term fundamentals, complicates benchmarking and elevates model risk for analysts and creditors relying on consistent historical metrics over the next 2–6 months.

Sandoz Group Ltd News

Sandoz announces U.S. FDA accepted for review two ANDAs for tirzepatide

Sandoz (SDZNY) announces that the US Food and Drug Administration, FDA, has accepted for review two Abbreviated New...

11d ago

Sandoz to Join Swiss Market Index in Milestone for Post-Listing Growth

Sandoz Group Ltd ( ($CH:SDZ) ) has shared an announcement. Sandoz has been selected for inclusion in the...

1d ago

Sandoz maps biosimilars ‘golden decade’ with capital markets day and Slovenia hub visit

Sandoz Group Ltd ( ($CH:SDZ) ) has provided an announcement. Sandoz Group AG, a leading global provider of...

18d ago

Sandoz opens flagship biosimilar R&D hub in Slovenia to anchor $1.1bn expansion

The latest announcement is out from Sandoz Group Ltd ( ($CH:SDZ) ). Sandoz has inaugurated a USD 99...

23d ago

Sandoz marks 80 years of European antibiotics and urges EU action to protect supply

An announcement from Sandoz Group Ltd ( ($CH:SDZ) ) is now available. Sandoz is marking 80 years of...

1M ago

Sandoz confirms the EC granted marketing authorization for Bysumlog, Dazparda

Sandoz (SDZNY) confirms that the European Commission, EC, has granted marketing authorization for Bysumlog and Dazparda. The two...

2M ago

Sandoz wins EU approval for two insulin biosimilars, bolstering diabetes push

Sandoz Group Ltd ( ($CH:SDZ) ) has shared an announcement. Sandoz has secured European Commission marketing authorisation for...

2M ago

Sandoz upgraded to Overweight from Equal Weight at Barclays

Barclays upgraded Sandoz (SDZNY) to Overweight from Equal Weight with an unchanged price target of CHF 75. The...

2M ago

Sandoz price target lowered to CHF 65 from CHF 70 at Deutsche Bank

Deutsche Bank lowered the firm’s price target on Sandoz (SDZNY) to CHF 65 from CHF 70 and keeps...

2M ago

Sandoz lifts Q1 sales on biosimilars surge and confirms 2026 outlook

Sandoz Group Ltd ( ($CH:SDZ) ) has provided an update. Sandoz reported first-quarter 2026 net sales of USD...

2M ago

Sandoz seals Rwanda supply deal to bolster access to critical medicines in Africa

An announcement from Sandoz Group Ltd ( ($CH:SDZ) ) is now available. Sandoz has signed a direct manufacturing...

3M ago

Sandoz price target raised to CHF 75 from CHF 66 at JPMorgan

JPMorgan analyst Sophia Graeff Buhl Nielsen raised the firm’s price target on Sandoz (SDZNY) to CHF 75 from...

3M ago

Sandoz marks 20 years of Omnitrope as biosimilar savings set stage for “golden decade”

Sandoz Group Ltd ( ($CH:SDZ) ) has shared an update. Sandoz is marking 20 years since the European...

3M ago

Sandoz investors back all AGM proposals, approve CHF 0.80 dividend

Sandoz Group Ltd ( ($CH:SDZ) ) has shared an announcement. Sandoz shareholders approved all Board of Directors’ proposals...

3M ago

SDZ FAQ

What was Sandoz Group Ltd’s price range in the past 12 months?

Sandoz Group Ltd lowest stock price was CHF43.66 and its highest was CHF74.72 in the past 12 months.

What is Sandoz Group Ltd’s market cap?

Sandoz Group Ltd’s market cap is CHF30.45B.

When is Sandoz Group Ltd’s upcoming earnings report date?

Sandoz Group Ltd’s upcoming earnings report date is Aug 05, 2026 which is in 26 days.

How were Sandoz Group Ltd’s earnings last quarter?

Sandoz Group Ltd released its earnings results on Feb 25, 2026. The company reported CHF1.638 earnings per share for the quarter, beating the consensus estimate of CHF1.4 by CHF0.239.

Is Sandoz Group Ltd overvalued?

According to Wall Street analysts Sandoz Group Ltd’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Sandoz Group Ltd pay dividends?

Sandoz Group Ltd pays a Annually dividend of CHF0.8 which represents an annual dividend yield of 1.02%. See more information on Sandoz Group Ltd dividends here

What is Sandoz Group Ltd’s EPS estimate?

Sandoz Group Ltd’s EPS estimate is 1.45.

How many shares outstanding does Sandoz Group Ltd have?

Sandoz Group Ltd has 440,000,000 shares outstanding.

What happened to Sandoz Group Ltd’s price movement after its last earnings report?

Sandoz Group Ltd reported an EPS of CHF1.638 in its last earnings report, beating expectations of CHF1.4. Following the earnings report the stock price went up 10.33%.

Which hedge fund is a major shareholder of Sandoz Group Ltd?

Currently, no hedge funds are holding shares in CH:SDZ

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Sandoz Group Ltd

Operating globally, Sandoz Group AG specializes in the development, production, and distribution of generic medications and biosimilar products. The company's portfolio includes the creation and sale of finished dosage forms for small molecule pharmaceuticals, often supplied to other entities. Sandoz is also a significant player in the biotechnology sector, providing protein-based products such as biosimilars and offering specialized manufacturing services within this field. Furthermore, it supplies anti-infective products, including active pharmaceutical ingredients (APIs) and intermediates, with a strong emphasis on antibiotics. Established in 1886, Sandoz maintains its headquarters in Rotkreuz, Switzerland.

Sandoz Group Ltd (SDZ) Earnings & Revenues

Historic Earnings Reports

SDZ Company Deck

SDZ Earnings Call

Q4 2026

0:00 / 0:00

Earnings Call Sentiment|Neutral

The earnings call presented a mixed picture with strong sales growth, particularly in the biosimilars segment and North American market recovery. However, the financial performance was impacted by negative free cash flow, a decline in core EBITDA margin, significant restructuring, and legal costs.View all CH:SDZ earnings summaries

SDZ Stock 12 Month Forecast

Average Price Target

CHF74.67

▲(11.18% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"41":"CHF41","62":"CHF62","83":"CHF83","51.5":"CHF51.5","72.5":"CHF72.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":82,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">CHF82.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":74.66666666666666,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">CHF74.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":65,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">CHF65.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[41,51.5,62,72.5,83],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,71.72,72.51076923076923,73.30153846153846,74.09230769230768,74.88307692307693,75.67384615384616,76.46461538461539,77.25538461538461,78.04615384615384,78.83692307692307,79.62769230769231,80.41846153846154,81.20923076923077,{"y":82,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,71.72,71.94666666666666,72.17333333333333,72.39999999999999,72.62666666666667,72.85333333333332,73.08,73.30666666666666,73.53333333333333,73.75999999999999,73.98666666666666,74.21333333333332,74.44,{"y":74.66666666666666,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,71.72,71.20307692307692,70.68615384615384,70.16923076923077,69.65230769230769,69.13538461538461,68.61846153846153,68.10153846153847,67.58461538461539,67.06769230769231,66.55076923076923,66.03384615384616,65.51692307692308,{"y":65,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":42.424,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.168,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":49.597,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44.173,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":52.857,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":56.058,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.145,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":60.524,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66.788,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.31,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":62.54,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":64.22,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":71.72,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >